Efficacy and Safety of Long Term Use of hCG or hCG Plus hMG in Males With Isolated Hypogonadotropic Hypogonadism (IHH)

Inclusion Criteria:

1. Age ≥ 18, ≤ 45 years old;

2. Adolescent dysplasia or loss of puberty: Genital Tanner score ﹤ 5, pubic hair Tannerscore ﹤ 5;

3. Serum FSH and LH levels are low or in normal low value, testosterone was lower thannormal range (1.75ng / ml, the lower limit of the normal blood testosterone referencerange of Tongji Hospital affiliated to Tongji Medical College, Huazhong University ofScience and Technology);

4. With or without olfactory loss/reduction;

5. Other pituitary hormone levels are normal;

6. Head MRI examination is normal;

7. Fertility is desired currently or will be desired in the future;

8. Understand and sign the informed consent form.

Exclusion Criteria:

1. Primary hypogonadism;

2. Acquired hypogonadotrophic hypogonadism;

3. A history of treatment with pulsed GnRH, hCG and FSH related hormones;

4. Receive testosterone replacement therapy for more than 6 months;

5. History of cryptorchidism or cryptorchidism;

6. The sperm density before treatment ≥1×10^6/ml;

7. Moderate or severe liver and kidney dysfunction (ALT>120IU/L, AST>80IU/L,CR>115μmol/L);

8. The karyotype is 45,X or 47,XXY and 48, XXXY and other abnormal karyotypes;

9. True hermaphroditism and pseudohermaphroditism;

10. Sex hormone abnormalities caused by adrenal lesions;

11. Hypogonadism secondary to other systemic diseases;

12. Abnormal secretion of hormones caused by brain lesions (such as pituitary tumors);

13. There are other hormone abnormalities in the pituitary;

14. There are contraindications for the treatment with hCG or hMG.